The Ng Teng Fong Charitable Foundation (NTFCF) donated RMB 50 million to Tsinghua University to establish a scientific research initiative under the ‘Tsinghua University Spring Breeze Fund’ (清華大學春風基金). The project focused on key areas such as anti-epidemic testing technology, epidemiology, and psychological rehabilitation.
This initiative led to a major breakthrough in the development of COVID-19 treatments. In 2021, China’s first neutralising antibody combination therapy—Ambavirumab injection (BRII-196) and Romisevirumab injection (BRII-198)—was approved by the National Medical Products Administration (NMPA). The therapy was officially launched in Mainland China on 8 July 2022, marking a significant milestone in the country’s fight against the pandemic.
